Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29210715 | 0.77 | PTGDR2 (0.56) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL3982874 | 0.77 | PTGDR2 (0.62) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL399302 | 0.76 | PTGDR2 (0.57) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL3982876 | 0.75 | PTGDR2 (0.65) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL4010208 | 0.72 | MGLL (0.44) | RAB9ANPC1ALDH1A1MAPK1MEN1 | |
| SCHEMBL16217687 | 0.70 | PTGDR2 (0.57) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL7140733 | 0.68 | PTGDR2 (0.51) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL21629618 | 0.67 | PTGDR2 (0.47) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL1542948 | 0.66 | PTGDR2 (0.56) | PTGDR2USP2ALPLALOX15SMN1; SMN2 | |
| SCHEMBL29426974 | 0.66 | PTGDR2 (0.56) | PTGDR2USP2ALPLALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | PTGDR2 1998/4885USP2 4144/4885ALPL 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.